Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, M.D., will participate in a panel discussion about the gastrointestinal microbiome at the 41st Annual Cowen Health Care Conference on March 2, 2021, at 11:10 AM ET. The discussion will be accessible via a live webcast on the company's investor website, with an archived replay available afterward. Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases, employing its proprietary Morphic Integrin Technology (MInT) Platform in collaboration with industry leaders.

WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to participate in a panel discussion on the gastrointestinal microbiome at the 41^st Annual Cowen Health Care Conference. The panel discussion will take place at 11:10 AM ET on Tuesday, March 2, 2021.

A live webcast of the panel will be available on the Investors section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary Morphic Integrin Technology (MInT) Platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397

FAQ

What is the date and time of the panel discussion featuring Morphic Therapeutic's CEO?

The panel discussion with Morphic Therapeutic's CEO is scheduled for March 2, 2021, at 11:10 AM ET.

How can I watch the panel discussion of Morphic Therapeutic at the Cowen Health Care Conference?

You can watch the live webcast of the panel discussion on the Investors section of Morphic Therapeutic's website.

What is the focus of Morphic Therapeutic's research and development?

Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases.

Who is participating in the panel discussion at the Cowen Health Care Conference?

Praveen Tipirneni, M.D., the CEO of Morphic Therapeutic, will participate in the panel discussion.

Where can I find more information about Morphic Therapeutic?

More information about Morphic Therapeutic can be found on their official website.